Bridging generics and biosimilars: new evidence, real-world impact, and regulatory debate to start Volume 15

Author(s): Robin Thorpe, PhD, FRCPath

In this first issue of 2026 (Volume 15), we feature two original research manuscripts—one in the generics field and the other on biosimilars—alongside one opinion and one special report, both of which address biosimilar topics.  The first Original Research, titled ‘A bioequivalence study of paliperidone palmitate once-monthly (156 mg/mL) extended-release injectable in patients with schizophrenia’, […]

Read more →